AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, cilt.12, ss.20-23, 2016 (ESCI İndekslerine Giren Dergi)
Although current and emerging treatment regimens are gaining traction in renal cell carcinoma (RCC) and bladder cancer, experts admit that the development of biomarkers to identify patients who will best respond to these treatments is still in a state of flux.